If you purchased Erasca, Inc. (ERAS) stock between January 14, 2025 and April 26, 2026, you must file your class action settlement claim by August 10, 2026 if you wish to seek lead plaintiff status—but this deadline should not create confusion about your eligibility for recovery. For example, an investor who bought 500 shares in February 2025 and held them through the class period should ensure they take action before the deadline if they lost more than $100,000, though doing so is not required to participate in any eventual settlement.
The deadline applies specifically to applications to serve as lead plaintiff; you can still participate in potential recovery without this formal role. The lawsuit centers on allegations that Erasca and its executives made false and misleading statements regarding the preclinical data for ERAS-0015, their lead drug candidate. According to the claims, the company improperly compared ERAS-0015 to Revolution Medicines’ product, raising questions about patent infringement and trade secret violations that the company did not adequately disclose to investors. This lawsuit was filed in the United States District Court for the Southern District of California, and affected investors are being urged to act quickly as the August 10, 2026 deadline approaches.
Table of Contents
- What Is the Erasca Class Action Lawsuit About?
- Who Can Participate in the Erasca Settlement?
- How Do You File Your Erasca Settlement Claim?
- Understanding Your Potential Recovery
- Key Deadlines and Important Dates
- What If You Have Losses Under $100,000?
- Contacting Lead Counsel Before the Deadline
What Is the Erasca Class Action Lawsuit About?
The core allegation involves Erasca’s statements about ERAS-0015’s preclinical capabilities. The company allegedly made claims about how ERAS-0015 performed in laboratory testing that were based on improper comparisons to Revolution Medicines’ technology, according to the lawsuit. This matters because such comparisons could indicate that Erasca’s drug infringes on Revolution Medicines’ patents or misappropriates trade secrets—a serious legal risk that could affect the value of the company and its securities.
Erasca investors allege they were not adequately informed about these intellectual property risks when they made their investment decisions. The class action covers investors who purchased Erasca stock during a specific window: January 14, 2025 through April 26, 2026. This period captures when the allegedly false statements were being made and when investors reasonably relied on them. The lawsuit targets both the company itself and the executives who made these statements, seeking compensation for investors who suffered losses as a result of the stock price decline that followed disclosure of these issues.
Who Can Participate in the Erasca Settlement?
Any investor who purchased Erasca common stock during the class period from January 14, 2025 through April 26, 2026 and suffered a loss is potentially eligible to participate in the settlement. This includes individual investors, retirement accounts that held the stock, and institutional investors. The lawsuit does not require you to have been aware of the allegations or to have made your purchase decision based on any particular knowledge—only that you purchased during the class period and have losses to show.
One important limitation: the deadline of August 10, 2026 applies only to applications for lead plaintiff status, which is a specific legal role in the case. Many investors with smaller losses, or those who simply do not wish to take on the lead plaintiff responsibilities, can still file claims for recovery without meeting this deadline. However, the lead plaintiff deadline should prompt action, as other claim deadlines typically follow and are more restrictive. Investors with losses exceeding $100,000 are specifically being reminded about August 10, 2026, making it a key date to monitor if you fall into that category.
How Do You File Your Erasca Settlement Claim?
If you are interested in serving as lead plaintiff—a role that typically involves working more closely with counsel and potentially being a named party in the case—you must submit your application by August 10, 2026. The lead plaintiff role comes with additional responsibilities and scrutiny but also gives you more influence over how the case proceeds. For most investors, however, waiting to file a standard claim after a settlement is reached is the simpler path and still allows full participation in any recovery.
To explore your options or begin the process, contact Lewis Kahn, Esq., Managing Partner at Kahn Swick & Foti, LLC, toll-free at 1-877-515-1850 or [email protected]. Having your account statements, purchase records, and loss calculations ready will streamline the conversation. The firm can explain whether lead plaintiff status makes sense for your situation or whether filing a claim after settlement would be more appropriate. Even if you do not pursue lead plaintiff status now, you should confirm with counsel what future deadlines will apply to protect your rights.
Understanding Your Potential Recovery
Settlement amounts in securities class actions depend on several factors: the strength of the case, the defendants’ ability to pay, and the number of eligible claimants. Because Erasca’s settlement has not yet been finalized, the exact recovery amount per share is unknown. However, investors are encouraged not to dismiss smaller positions—sometimes the per-share recovery is modest, but multiplied across thousands or millions of shares affected, it can be meaningful in aggregate.
One common misconception is that only large investors recover. In practice, settlement distributions are typically proportional to loss: if you lost $50,000 on Erasca stock, your recovery (before attorneys’ fees and court costs) would be calculated as a percentage of the total settlement fund based on your proportional share of losses. This means smaller investors do recover, though their checks may also be smaller. The comparison is important: while a settlement for $10 million covering 100,000 affected shareholders might yield $100 per shareholder on average, an investor with losses of $200,000 could recover significantly more than someone with losses of $10,000.
Key Deadlines and Important Dates
August 10, 2026 is the critical date for lead plaintiff applications. Once this deadline passes, the opportunity to serve in that role closes unless a court extends it. After the lead plaintiff is appointed, the case will move through discovery, motions, and eventually toward settlement—a process that typically takes one to three years or longer in complex securities litigation.
Following the lead plaintiff appointment, the court will set subsequent deadlines for claim filing, and those dates are when other investors will have their final opportunity to participate. What happens between now and August 10 is important: if you believe you qualify, reach out to counsel before the deadline to discuss your options. The lead plaintiff deadline should not be ignored simply because you think your losses are too small—some investors with modest losses have chosen to serve as lead plaintiffs if they were willing to take on the role. However, if you are certain you do not want that responsibility, you can wait for claim filing deadlines that will come later, knowing that other critical dates will apply at that stage.
What If You Have Losses Under $100,000?
While notices have specifically highlighted investors with losses exceeding $100,000, investors with smaller losses are equally eligible to participate in the settlement. The focus on the $100,000 threshold in recent alerts reflects the lead plaintiff deadline and the target audience of those notices, not an eligibility cutoff. An investor who lost $75,000, $50,000, or even $10,000 can still file a claim and recover their proportional share if the settlement is approved.
The distinction is practical rather than legal: investors with very large losses have more incentive to pursue lead plaintiff status because the effort and involvement might justify the oversight role. Investors with modest losses might find it simpler to wait and file a standard claim later. Either approach—lead plaintiff application or future claim filing—protects your rights, but only if you remain aware of the upcoming deadlines.
Contacting Lead Counsel Before the Deadline
Lewis Kahn, Esq., at Kahn Swick & Foti, LLC is the primary contact for questions about the lead plaintiff deadline and your potential involvement. The toll-free number 1-877-515-1850 and email [email protected] are available to discuss your specific situation, answer questions about the case timeline, and clarify what lead plaintiff status entails. Calls made before August 10, 2026 ensure your inquiry is handled within the deadline window.
When you reach out, have your purchase records and loss statements available. The counsel can advise whether your circumstances fit the lead plaintiff profile and what steps to take next if you are interested in that role. If you prefer not to serve as lead plaintiff, the firm can explain when you will need to act to file a standard claim once a settlement is reached and approved.
- —